×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Drugs and Devices

On Nov. 28, the FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

Read more via U.S. Food . . .

According to the National Youth Tobacco Survey, more than 3.6 million middle and high school students are current (past 30 day) e-cigarette users in 2018, an increase of more than 1.5 million students since last year.

Read more via U.S. Food & Drug Administration . . .

A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation, according to a study Proceedings of the National Academy of Sciences.

Read more via The James The Ohio State University Comprehensive Cancer Center and access the study abstract via . . .

On Oct. 5, the U.S. Food and Drug Administration (FDA) approved expansion of the use of Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) to include women and men aged 27 through 45 years.

Read more via U.S. Food & Drug Administration . . .

Consuming one to two drinks four or more times per week, which is deemed healthy by current guidelines, increases the risk of premature death by 20%, compared with drinking three times a week or less, according to a study in Alcoholism: Clinical & Experimental Research.

Read more via Washington University . . .

On August 10, U.S. Food and Drug Administration (FDA) approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women and is the first vaginal ring contraceptive that can be used for an entire year.

Read more via U.S. Food & Drug . . .

On August 8, the U.S. Food and Drug Administration (FDA) approved Poteligeo (mogamulizumab-kpkc) injection for IV use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. These are two rare, hard-to . . .

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing